Balyasny Asset Management’s Enfusion, Inc. ENFN Stock Holding History

Balyasny Asset Management’s Portfolio ENFN Stock Details ENFN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,925,962	Closed	-$21.5M	–	3497
2025 Q1	$21.5M	Buy	1,925,962 +1,879,019	+4,003%	+$20.8M	0.04%	567
2024 Q4	$484K	Buy	46,943 +25,017	+114%	+$242K	﹤0.01%	2205
2024 Q3	$208K	Buy	+21,926	New	+$189K	﹤0.01%	2552
2022 Q4	–	Sell	-14,327	Closed	-$177K	–	3317
2022 Q3	$177K	Buy	+14,327	New	+$175K	﹤0.01%	2331
2022 Q1	–	Sell	-119,555	Closed	-$2.5M	–	2927
2021 Q4	$2.5M	Buy	+119,555	New	+$2.42M	0.01%	1122

Other funds holding ENFN

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Balyasny Asset Management's ENFN Position: Q2 2025 in Review

Balyasny Asset Management sold out of Enfusion, Inc. (ENFN) in Q2 2025, closing a stake of 1,925,962 shares — an estimated $21.5M sold.

Balyasny Asset Management first reported a position in ENFN in Q4 2021 and held it in 5 quarters. The position peaked at $21.5M in Q1 2025. 2 funds tracked by Wall St. Rank hold ENFN as of Q2 2025.

Balyasny Asset Management reported no remaining Enfusion, Inc. position as of Q2 2025 after selling out during the quarter.
Balyasny Asset Management sold 1,925,962 Enfusion, Inc. shares in Q2 2025, an estimated $21.5M.
Balyasny Asset Management first reported a position in Enfusion, Inc. in Q4 2021 and held it in 5 quarters.
Balyasny Asset Management's Enfusion, Inc. position peaked at $21.5M in Q1 2025.
2 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.